ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.
ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.
ABSTRACTS â ORAL PRESENTATIONS - AMCA, spol. s r.o.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
that the interaction of MPO with glycocalyx GAGs can lead to collapse of the glycocalyx<br />
structure. In order to get an insight into the mechanism how MPO may affect this, MPO<br />
mediated modulation of viscosity of GAGs solution as a degree of modulation of GAG<br />
three dimensional structure was determined. Data show a remarkable MPO mediated<br />
increase of the viscosity of two model GAGs hyaluronate and chondroitin sulphate.<br />
Further, MPO mediated decrease of GAG intrinsic negative charge at physiological<br />
conditions was evaluated. Different experimental settings were tested to stabilize GAGs<br />
in three dimensional structures which allowed the determination of the charge change<br />
employing dyes alcian blue X8 or direct red. Results suggest that staining with both dyes<br />
corresponds in a linear manner to the amount of embedded GAGs and that cationic<br />
proteins decrease the overall charge of embedded GAGs. Interestingly, similar effect was<br />
observed in vivo in mouse after application of alcian blue into the carotid artery and<br />
consequent loss of staining after application of MPO.<br />
These findings extend the knowledge of MPO inflammatory properties in vascular<br />
inflammation.<br />
Acknowledgements<br />
This work was supported by grants from the Czech Science Foundation No. P305/12/<br />
J038 and from DFG BA1870/9-1; KL 2516/1-1 and the European Social Fund - Project<br />
OganoNET (CZ.1.07/2.4.00/31.0245) and HistoPARK (CZ.1.07/2.3.00/20.0185). LK was<br />
supported by the European Regional Development Fund - Project FNUSA-ICRC (No.<br />
CZ.1.05/1.1.00/02.0123).<br />
P17. ROSIGLITAZONE ACTS AS AN EFFICIENT MODULATOR OF LA-12-INDUCED<br />
CYTOTOXIC AND CYTOSTATIC RESPONSE OF COLON CANCER CELLS<br />
Jarmila Lauková 1,2,3 , Iva Jelínková 1,2 , Jiřina Hofmanová 1,2 , Nicol Straková 1,6 , Petr Sova 4 , Jiří<br />
Ehrmann 5 , Zdeněk Kolář 5 , Alois Kozubík 1,2 and Alena Hyršlová Vaculová 1,3<br />
1<br />
Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech<br />
Republic, v.v..i., Brno, Czech Republic; laukova@ibp.cz, vaculova@ibp.cz<br />
2<br />
Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech<br />
Republic<br />
3<br />
Center of Biomolecular and Cellular Engineering, International Clinical Research Center,<br />
St. Anne´s University Hospital Brno, Czech Republic<br />
4<br />
Platinum Pharmaceuticals, a.s., Brno, Czech Republic<br />
5<br />
Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry,<br />
Palacky University Olomouc, Czech Republic<br />
Rosiglitazone, a synthetic ligand of peroxisome proliferator-activated receptor gamma<br />
(PPARgamma) can suppress proliferation and stimulate death of colon cancer cells.<br />
In addition, it may also act as an agent sensitizing the cancer cells to the action of<br />
selected chemotherapeutic drugs, which suggests its potential application in antitumor<br />
therapy. Our results showed that pretreatment of HCT116 human colon cancer cells<br />
with rosiglitazone resulted in enhancement of apoptosis induced by platinum (IV)<br />
Analytical Cytometry VII 107